These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11233295)

  • 21. [Neuropsychiatric disorders caused by organic solvents].
    von Bose M; Zaudig M
    Psychiatr Prax; 1991 Jan; 18(1):25-9. PubMed ID: 2027914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe dopaminergic pathways damage in a case of chronic toluene abuse.
    Papageorgiou SG; Karantoni E; Pandis D; Kouzoupis AV; Kalfakis N; Limouris GS
    Clin Neurol Neurosurg; 2009 Dec; 111(10):864-7. PubMed ID: 19651471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The amotivational syndrome and cannabis use with emphasis on the Canadian scene.
    Campbell I
    Ann N Y Acad Sci; 1976; 282():33-6. PubMed ID: 1071387
    [No Abstract]   [Full Text] [Related]  

  • 24. [Dementia following bipolar disorder].
    Lebert F; Lys H; Haëm E; Pasquier F
    Encephale; 2008 Dec; 34(6):606-10. PubMed ID: 19081458
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Frontal symptoms, self-perceived stress, and subjective memory complaints in substance abusers].
    Terán-Mendoza O; Sira-Ramos D; Guerrero-Alcedo J; Arroyo-Alvarado D
    Rev Neurol; 2016 Apr; 62(7):296-302. PubMed ID: 26988167
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Depression and frontal dysfunction: risks for the elderly?].
    Thomas P; Hazif Thomas C; Billon R; Peix R; Faugeron P; Clément JP
    Encephale; 2009 Sep; 35(4):361-9. PubMed ID: 19748373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of MRI abnormalities on WAIS-R performance in solvent abusers.
    Yamanouchi N; Okada S; Kodama K; Sakamoto T; Sekine H; Hirai S; Murakami A; Komatsu N; Sato T
    Acta Neurol Scand; 1997 Jul; 96(1):34-9. PubMed ID: 9262130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What is the evidence for an amotivational syndrome in cannabis users?
    Farnsworth DL
    Ann N Y Acad Sci; 1976; 282():1. PubMed ID: 1071372
    [No Abstract]   [Full Text] [Related]  

  • 29. Psychiatric aspects of cannabis use in adolescents and young adults.
    Tunving K
    Pediatrician; 1987; 14(1-2):83-91. PubMed ID: 3497393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical features of recent methamphetamine abusers: comparison between smoking abusers and injection abusers].
    Matsumoto T
    Seishin Shinkeigaku Zasshi; 2000; 102(5):498-513. PubMed ID: 10897680
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical characteristics of dappou herb use--disorder patients at the drug dependence clinic: a comparison with methamphetamine use-disorder patients].
    Tanibuchi Y; Matsumoto T; Kobayashi O; Wada K
    Seishin Shinkeigaku Zasshi; 2013; 115(5):463-76. PubMed ID: 23855225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frontal lobe volume in patients with Huntington's disease.
    Aylward EH; Anderson NB; Bylsma FW; Wagster MV; Barta PE; Sherr M; Feeney J; Davis A; Rosenblatt A; Pearlson GD; Ross CA
    Neurology; 1998 Jan; 50(1):252-8. PubMed ID: 9443488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cannabis and work in Jamaica: a refutation of the amotivational syndrome.
    Comitas L
    Ann N Y Acad Sci; 1976; 282():24-32. PubMed ID: 1071382
    [No Abstract]   [Full Text] [Related]  

  • 34. Assessment of attention and memory efficiency in persons with solvent neurotoxicity.
    Morrow LA; Robin N; Hodgson MJ; Kamis H
    Neuropsychologia; 1992 Oct; 30(10):911-22. PubMed ID: 1436437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cortical and frontal atrophy are associated with cognitive impairment in age-related confluent white-matter lesion.
    Mok V; Wong KK; Xiong Y; Wong A; Schmidt R; Chu W; Hu X; Leung EY; Chen S; Chen Y; Tang WK; Chen X; Ho CL; Wong KS; Wong ST
    J Neurol Neurosurg Psychiatry; 2011 Jan; 82(1):52-7. PubMed ID: 20826875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Psychological problem due to long-term organic solvent abuse].
    Kobayashi T; Fukui K; Hayakawa S; Koga E; Ono I; Fukui Y; Tani N; Kato A; Nakajima T
    Arukoru Kenkyuto Yakubutsu Ison; 1995 Oct; 30(5):358-66. PubMed ID: 8534223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toluene misuse and long-term harms: a systematic review of the neuropsychological and neuroimaging literature.
    Yücel M; Takagi M; Walterfang M; Lubman DI
    Neurosci Biobehav Rev; 2008 Jul; 32(5):910-26. PubMed ID: 18456329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve first-episode psychosis patients.
    Goghari VM; Smith GN; Honer WG; Kopala LC; Thornton AE; Su W; Macewan GW; Lang DJ
    Schizophr Res; 2013 Sep; 149(1-3):149-55. PubMed ID: 23830856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Akinesia, tardive dysmentia, and frontal lobe disorder in schizophrenia.
    Goldberg E
    Schizophr Bull; 1985; 11(2):255-63. PubMed ID: 2861656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Substance abuse and schizophrenia: effect on symptoms but not on neurocognitive function.
    Cleghorn JM; Kaplan RD; Szechtman B; Szechtman H; Brown GM; Franco S
    J Clin Psychiatry; 1991 Jan; 52(1):26-30. PubMed ID: 1671032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.